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ttp://dx.doi.org/10.1016/j.jmoldx.2013.10.010Aberrant regulation of DNA methylation is characteristic of cancer cells and clearly inﬂuences pheno-
types of various malignancies. Despite clear correlations between DNA methylation and patient
outcome, tests that directly measure multiple-locus DNA methylation are typically expensive and
technically challenging. Previous studies have demonstrated that the prognosis of patients with acute
myeloid leukemia can be predicted by the DNA methylation pattern of 18 loci. We have developed a
novel strategy, termed microsphere HpaII tiny fragment enrichment by ligation-mediated PCR (MELP),
to simultaneously analyze the DNA methylation pattern at these loci using methylation-speciﬁc DNA
digestion, ﬂuorescently labeled microspheres, and branched DNA hybridization. The method uses
techniques that are inexpensive and easily performed in a molecular laboratory. MELP accurately reﬂects
the methylation levels at each locus analyzed and segregates patients with acute myeloid leukemia into
prognostic subgroups. Our results demonstrate the usefulness of MELP as a platform for simultaneous
evaluation of DNA methylation of multiple loci. (J Mol Diagn 2014, 16: 207e215; http://dx.doi.org/
10.1016/j.jmoldx.2013.10.010)This work was supported, in part, by the JP McCarthy Foundation
(G.B.W.W.andA.B.),VeteransAffairsAdministrationgrant 1I01BX000918-
01 (M.C.), and NIH grant 1R01CA149566-01A1 (M.C.).
Disclosures: None declared.Cancer has been traditionally considered a genetic disease,
involving a series of mutations that activate oncogenes and
inactivate tumor suppressors.1 Although mutagenic events
are critical for carcinogenesis, recent work has unequivo-
cally demonstrated that cancer is also characterized by
dysregulation of chromatin structure that involves the DNA
itself (eg, CpG methylation) and its associated histones.2
Because these epigenetic modiﬁcations are at least par-
tially responsible for inﬂuencing tumorigenic processes, it is
not surprising that several studies have demonstrated that
prognosis of certain tumors can be predicted from analysis
of epigenetic features.3e5
An example of a tumor type that shows clear dysregula-
tion of epigenetic modiﬁcations is acute myeloid leukemia
(AML).6,7 Many of the recurrent mutations seen in AML,
including those in DNMT3A, IDH1, IDH2,MLL, and EZH2,
inﬂuence DNA methylation, DNA hydroxymethylation, or
histone modiﬁcation.8e11 Dysregulated DNA methylation at
speciﬁc loci, such as CDKN2B and MGMT, has been foundstigative Pathology
.in many cases of AML.12 Moreover, studies of global
methylation have shown DNA methylation in leukemic
blasts is distinct from that seen in normal CD34þ cells, and
that DNA methylation patterns alone can segregate AML
samples into categories with signiﬁcant clinical and bio-
logical features.3 Indeed, a DNA methylation analysis using
only 18 loci was shown to distinguish prognostic subgroups
of AML, and this methylation-based classiﬁer retained sig-
niﬁcance in a multivariate analysis that included factors
used clinically for determining patient prognosis.3
Despite the clear implications of epigenetics for tumor
biological features and patient prognosis, studies involving
multiple-locus DNA methylation of cancers have lagged
behind those assessing DNA sequence variations. One reason
Wertheim et alis the lack of robust multiplex assay platforms that are
amenable for high-throughput laboratory use.Most assays that
probe DNA methylation are technically challenging because
they use sodium bisulﬁte treatment of DNA, which can cause
sample degradation.13,14 In addition, examination of methyl-
ation at multiple loci requires either nucleotide microarrays or
high-throughput sequencing technologies, both of which
require extensive investment for materials and equipment.
To circumvent the technical challenges involved in routine
epigenetic analysis, we have developed a novel method to
determine DNA methylation status that uses analytical tech-
niques commonly used in molecular laboratories. As a proof
of principle of the utility of this assay and to directly compare
it with well-established tests for DNA methylation, we have
applied our novel technique to measure DNA methylation at
18 loci previously shown to carry prognostic signiﬁcance in
patients with AML.3 Our method, conceptually based on the
HpaII tiny fragment enrichment by ligation-mediated PCR
(HELP) assay, does not use bisulﬁte treatment. Rather, it uses
methylation-sensitive restriction digestion, followed by oli-
gonucleotide ligation and PCR.15 Examination of methyl-
ation levels is performed by ﬂow cytometric analysis of
ﬂuorescent microspheres, thereby alleviating the need for
microarrays or high-throughput sequencing technologies.We
demonstrate that this methylation assay, designated micro-
sphere HELP (MELP), accurately recapitulates genome-wide
HELP of AML samples, both in terms of DNA methylation
status at individual loci and with a global classiﬁer relating
DNA methylation to patient outcome. Thus, MELP may
prove to be an appropriate technology for evaluation of DNA
methylation in diseases associated with dysregulated epige-
netic status.
Materials and Methods
Samples and DNA Preparation
Samples for the development of MELP and the comparison
between HELP and MELP were from patients treated on
study protocols of the Dutch-Belgian Hemato-Oncology
Cooperative Group (HOVON) and have been previously
described.3 The sets of patients used as training, test, and
validation cohorts are all from this group of patients, and the
samples in each cohort were drawn from those previously
studied.3 Additional samples to establish initial characteris-
tics of MELP are primary deidentiﬁed AML apheresis sam-
ples purchased from the Stem Cell and Xenograft Core of the
University of Pennsylvania (Philadelphia). All samples were
obtained after patient consent on a University of Pennsyl-
vania Institutional Review Boardeapproved protocol and
cryopreserved as viable cells in 10% dimethyl sulfoxide.
DNA Preparation and Ligation-Mediated PCR
Procedures for preparing DNA and performing ligation-
mediated PCR have been previously described.3 Brieﬂy,208DNA preparation from 5 million cells was performed with
the Qiagen Puregene kit (Qiagen, Valencia, CA), following
the manufacturer’s protocol for DNA extraction from buffy
coat samples. MspI, HpaII (NEB, Ipswich, MA), and mock
digests of 1 mg of DNA were performed at 37C overnight,
followed by 16C overnight T4 ligase-mediated ligation of
pre-annealed JHpaII 12 and JHpaII 24 linkers. Subsequent
PCR ampliﬁcation using JHpaII 24 primers was performed
as described. For most reactions, PCR was performed in 100
mL total volume for 20 cycles. For reactions in which input
DNA was serially diluted, PCR with 11 cycles of ampliﬁ-
cation was performed.
Real-Time PCR
PCR products from eight primary AML samples from the
HOVON cohort were diluted 1:20 in PCR-grade water.
Quantitative PCRs with 1 mL of the diluted products in 20
mL total volume were performed using SYBR Green PCR
master mix (Applied Biosystems, Foster City, CA) with the
same PCR conditions as those used in the initial PCR. Real-
time PCR primers (ﬁnal concentration, 200 nmol/L) were as
follows:B2M forward, 50-TTTCTGGCCTGGAGGCTATC-30;
B2M reverse, 50-ACGGAGCGAGAGAGCACAG-30; E2F1
forward, 50-CAGCCATCAGCCACCTCTTC-30; E2F1 re-
verse, 50-TTCCAGGCACCGCTCTTC-30; chromosome X
locus forward, 50-CCAGAAGGCTGGCACACA-30; and
chromosome X locus reverse, 50-AAGTGCAGCGTCAG-
CAAGAG-30.
Quantigene 2.0 Hybridization
Prognostic loci used for the Quantigene 2.0 (Affymetrix, Santa
Clara, CA) hybridization panel have been described previ-
ously3 and are listed in Supplemental Table S1. The three loci
used for normalization are as follows (human genome assem-
bly GRCh37/hg19): normalization A) chr6: 34856156-
34857019; normalization B) chr13: 53028642-53029495; and
normalization C) chr19: 37958559-37955860. Sequential hy-
bridization reactions for complexing amplicons onto ﬂuores-
cent microspheres and for branched DNA signal ampliﬁcation
were performed with the Quantigene 2.0 assay, following the
manufacturer’s protocol for RNA hybridization (Affymetrix).
Speciﬁcally, 8 mL PCRs were incubated at room temperature
using 5mLof2.5mol/LNaOH, 5mLof the locus-speciﬁc probe
mixture, and 5 mL of lysis mixture (the latter two products
provided in the Quantigene 2.0 assay) in 68 mL total volume.
The reaction was neutralized by addition of 36 mL of 2 mol/L
HEPES buffer. This amplicon/probemixturewas added to a 20
mL reaction mix consisting of 0.2 mL of proteinase K, 15 mL of
lysis mixture, 2 mL of blocking reagent, and 1 mL of locus-
speciﬁc ﬂuorescent microspheres (all products provided in
the Quantigene 2.0 assay). These hybridizations were incu-
bated with shaking at 55C overnight. Reactions were placed
on a magnet and washed three times with wash buffer (pro-
vided in the Quantigene 2.0 assay). The reactions were thenjmd.amjpathol.org - The Journal of Molecular Diagnostics
Microsphere DNA Methylation Assaysequentially hybridized to pre-ampliﬁer, ampliﬁer, and bio-
tinylated label-probe DNA in 100 mL of the appropriate buffer
(provided in theQuantigene 2.0 assay).All hybridizationswere
performed for 1 hour at 50Cwith shaking. Each hybridization
wasprecededbymagneticbeadcapture and threewashes.After
hybridizations, the reactionwas incubated at room temperature
with 4 mg/mL streptavidin-phycoerythrin in the appropriate
buffer (supplied by the manufacturer). After three washes, the
ﬂuorescent microspheres were analyzed by ﬂow cytometry on
a FLEXMAP three-dimensional instrument running xPO-
NENT 4.0 software (Luminex Corporation, Austin, TX). The
entire procedurewas performed separately for products derived
from MspI-digested, HpaII-digested, or mock-digested DNA.
Amount of bound product was determined by phosphatidyl-
ethanolamine signal, whereas locus identitywas determined by
ﬂuorescence signal of each microsphere. Relative methylation
was determined by the ratio of phosphatidylethanolamine
median ﬂuorescence intensity of each locus in MspI-digested
and HpaII-digested samples normalized to the same ratio of
known hypomethylated loci.
Normalization
To identify unmethylated control loci for normalization, we
selected a list of 26 candidates for which measurements were
available in at least 340 samples and that met criteria based on
the width of the distribution across samples and the absence
of methylated outliers (density maximum, >0.55; minimum
value,>1 across all samples; mean value,<4). From this list,
three loci (MSPI0406S00318682,MSPI0406S00653944, and
MSPI0406S00890278) were chosen to represent an unme-
thylated baseline within each sample. HELP or MELP
methylation values were normalized by obtaining the ratio
with the average methylation score from the three unme-
thylated control loci. In the case of HELP, the original data
had previously undergone global normalization; thus, ()
normalization reﬂects this original normalization, whereas
(þ) normalization reﬂects the further transformation of the
HELP data using the ratio to control loci previously
described.
Data Sources and Statistical Analysis
All statistical analyses were performed using the R statistical
package (http://www.r-project.org). R scripts and tumor
sublists used to generate the results for this article are avail-
able as Supplemental Scripts S1, S2, S3, S4, and S5. MELP
expression values and HOVON tumor data are available as
Supplemental Tables S2 and S3. Raw MELP data ﬁles were
preprocessed using an in-house Perl script. HELP data have
been previously published3 (Gene Expression Omnibus; http://
www.ncbi.nlm.nih.gov/geo; accession number GSE18700) and
represent values that had been processed by global normali-
zation. MassArray correlation ﬁles and subject survival data
were provided by the authors.3 Comparisons between mea-
surement modalities were performed using the PearsonThe Journal of Molecular Diagnostics - jmd.amjpathol.orgcorrelation coefﬁcient. To convert from HELP to MELP
values, Deming regression was performed on training data
using the MethComp package in R (http://www.r-project.org).
Multiplex Methylation Scores for AML
The level of methylation at a single locus is deﬁned by the
normalized ratio of the signal from the HpaII- and the MspI-
digested sample. To assign a given sample to a survival
group, a predictor model was trained on the 18 loci previ-
ously reported by Figueroa et al.3 Training, testing, and
validation of this model were performed using the respective
HOVON sample sets previously speciﬁed.3 Brieﬂy, we
obtained HELP values for the 18 predictive loci from the
training group (n Z 200, the original HOVON HELP
training data3). Of these samples, 84 were rerun using
MELP, and Deming regression was used to convert HELP-
derived values for the entire 200 training samples (including
the 84 on which MELP was directly performed) to MELP-
scale values. Methylation values of the test set (nZ 84) and
validation set (n Z 48) were obtained directly by MELP.
The training set was used to build the classiﬁcation model,
and model coefﬁcients were reﬁned using the training and
test sets, as previously described.3 A methylation outcome
score (MS) is given as follows:
MSZaðL1Þ þ bðL2Þ þ cðL3Þ þ dðL4Þ:::þ rðL18Þ; ð1Þ
where L# is the methylation level (ie, normalized HpaII/MspI
ratio) at each locus, and the associated constant (a, b, c) is the
weighting factor, as determined by our training algorithm
(SuperPC; http://statweb.stanford.edu/wtibs/superpc). Each
tumor in the training set receives a methylation outcome
score, and cutoffs are determined by using scores that segre-
gate the training set into thirds (tertiles). Tumors in the test and
validation subsets were segregated according to these cutoffs,
and survival was determined.
Results
Because the HELP assay avoids sodium bisulﬁte treatment and
was previously used to establish a DNA methylation-based
classiﬁer forAMLprognosis,3wemodiﬁed this assay tomake it
more feasible for routine use. The HELP assay (Figure 1A)
involves DNA digestion by the methylation-insensitive re-
striction endonuclease MspI or its methylation-sensitive iso-
schizomer, HpaII. After digestion, oligonucleotides are ligated
onto fragment ends and linker-mediated PCR is performedwith
Taq polymerase.15 The conditions of polymerization favored
the ampliﬁcation of smaller fragments, which are ﬂuorescently
labeled and hybridized to custom-made oligonucleotide
microarrays. Regions with relative hypomethylation should
display similar levels of hybridization from both MspI- and
HpaII-derived products, whereas those with relative hyper-
methylation should have a predominance of MspI-derived
products. The MELP modiﬁcation (Figure 1B) that we
introduced replaces the oligonucleotide microarray with209
Figure 1 A: Schematic of the HELP assay. Genomic DNA is digested with either MspI (methylation insensitive) or HpaII (methylation sensitive). The
resulting fragments are ligated to linkers and PCR ampliﬁed with linker-speciﬁc primers. Amplicons are ﬂuorescently labeled (as shown, red for amplicons from
MspI-digested genomic DNA and green for HpaII-digested genomic DNA) and hybridized to oligonucleotide microarrays. Only relatively short fragments are
ampliﬁed by Taq polymerase. Regions of relative hypomethylation will show signal from both MspI- and HpaII-digested DNA, whereas regions of relative
hypermethylation will show a predominance of MspI signal. B: MELP modiﬁcation of HELP assay. Rather than hybridizing to oligonucleotide arrays, amplicons
(with red and green denoting the initial MspI and HpaII digests, respectively) are hybridized to oligonucleotides covalently linked to ﬂuorescent microspheres
with distinct ﬂuorescent properties (depicted as shades of brown). The microspheres are subjected to ﬂow cytometry and analyzed for locus/microsphere
identity (determined by brown intensity) and for amplicon amount (determined by red/green intensity).
Wertheim et alﬂuorescently labeled microspheres covalently coupled to
oligonucleotides speciﬁc for the loci in the HELP-derived
AML classiﬁer. PCR products are hybridized onto these
microspheres and are detected by using a ﬂow cytometer,
rather than by microarray scanning. Fluorescence properties
of the microspheres identify the speciﬁc locus, and the
relative signal intensity of the hybridized PCR products re-
ﬂects level of methylation. These modiﬁcations make the
assay highly feasible for routine use, because detection of
ﬂuorescent microspheres by ﬂow cytometry has been
adapted in several other assays.16,17
Initial tests using oligonucleotide-coupled microspheres
for product detection demonstrated that we could specif-
ically hybridize amplicons from the linker-mediated PCR
onto ﬂuorescent microspheres; however, the ﬂuorescence
intensity from the labeled PCR products was lower than the
detection limit of the instrument. Increasing the number of
PCR cycles from 20 (standard for HELP) to 55 did not lead
to a subsequent increase in signal intensity, suggesting that
the PCR saturates (data not shown). Thus, a method to
linearly amplify signal from a ﬁxed number of amplicons
was required. Because the use of branched DNA technology
has been shown to speciﬁcally detect femtogram amounts of
nucleic acids, we altered our detection method to incorpo-
rate a series of branched DNA hybridization reactions
(QuatigenePlex 2.0 technology; Affymetrix) before anal-
ysis. This technology has been used for RNA expression but210is less well characterized for DNA and has never been used
to analyze DNA methylation.
Multiplex MELP Linearity and Speciﬁcity
Given the novelty of the assay technology used, we ﬁrst
determined if the assay is quantitative, and if it could be used
to accurately determine the relative amounts of PCR products
from the MspI and HpaII reactions. To this end, we digested
genomic DNA from primary AML samples with MspI, per-
formed linker-mediated PCR, and detected ﬂuorescent signal
from speciﬁc PCR products after both hybridization to mi-
crospheres and branched DNA signal ampliﬁcation. As
shown in Figure 2, A and B, reproducible levels of ﬂuores-
cence are seen for each locus, and a 10-fold dilution of PCR
product results in a similar decrease in signal intensity. As
expected, the assay requires restriction enzyme digest,
because use of either undigested DNA or no DNA yields
minimal signal. In addition, absolute median ﬂuorescent in-
tensities range from <100 to >20,000. Thus, the linearity of
the assay appears to extend over at least a 2-log range.
Because the negative controls typically display a median
ﬂuorescent intensity of<10, the linearity is likely to be close
to a 3-log range. This 3-log range of linearity is consistent
with results using the QuantigenePlex 2.0 assay to quantitate
RNA expression.18 Overall, these controls demonstrate linear
ampliﬁcation and detection of MspI-digested PCR products.jmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 2 The MELP assay is both quantitative and speciﬁc. A and B: Linker-mediated ampliﬁcation of MspI-digested DNA was performed. Amplicons were
hybridized to ﬂuorescent microspheres and detected by branched DNA hybridization. A 1:10 dilution of amplicons is also assayed. Results are shown for two
independent primary AML samples at E2F1 (A) and an unnamed locus on chromosome X (B), both of which are in the HELP-deﬁned methylation classiﬁer for
AML. C: A similar assay to A and B was performed, but input DNA was diluted 1:2, 1:4, and 1:10, rather than amplicon dilution, as in A and B. Results are
shown for the two loci in A and B and for B2M. In addition, ﬂuorescent microspheres coupled to nonspeciﬁc oligonucleotides were included to determine
background signal. D and E: Relative amplicon quantitation by MELP compared with quantitation by PCR. MELP was performed on primary AML samples, and
signal ratio from MspI and HpaII digests of E2F1 (D) and an unnamed locus on chromosome X (E) were normalized to ratios of the hypomethylated locus, B2M.
Amplicon quantitation was also determined by locus-speciﬁc qPCR. MFI, mean ﬂuorescent intensity.
Microsphere DNA Methylation AssayWe further sought to determine whether the assay accu-
rately reﬂects the number of digested genomic fragments
from the original sample, rather than simply the number of
amplicons in the ﬁnal PCR product. We, therefore, per-
formed a similar assay as previously described, but rather
than diluting the ﬁnal product, we performed 2-, 4-, and 10-
fold dilutions on the MspI-digested sample before PCR. As
shown in Figure 2C, the fold decrease in signal intensity
closely approximates the fold dilution of the starting mate-
rial. In addition, virtually no signal was obtained with
ﬂuorescent microspheres that are covalently coupled to non-
speciﬁc oligonucleotides, thus conﬁrming the speciﬁcity of
the assay.
As a ﬁnal veriﬁcation of the quantitative accuracy and the
locus speciﬁcity of our detection method, we compared
detection and quantitation by our hybridization method with
quantitative PCR (qPCR). The entire MELP assay (including
branched DNA hybridization and ﬂow cytometry) was per-
formed on DNA from eight primary AML samples and
analyzed MspI- and HpaII-derived products at two loci that
are part of the HELP-determined methylation classiﬁer. In
parallel, we performed the same assay but used qPCR for
amplicon quantitation at these two loci. Furthermore, a
known hypomethylated locus, B2M (b2 microglobulin), wasThe Journal of Molecular Diagnostics - jmd.amjpathol.organalyzed in both assays for signal normalization.3 As shown
in Figure 2D, the normalized ratios of MspI and HpaII
products are virtually identical between the two assays at
both loci, indicating that our method of detection is as spe-
ciﬁc and as quantitative as qPCR.
Normalization of DNA Methylation Measurements
Given the robust performance of the MELP assay with a
limited number of loci, we expanded it to encompass the
entire 18-locus classiﬁer used in the HELP assay to predict
AML outcomes. However, one advantage of highly multi-
plexed HELP results that is not shared by results obtained by
MELP is that expression values can be normalized using
global array properties. In the absence of global normaliza-
tion, it is necessary to compare measured values with those
found in a known unmethylated locus. Although mitochon-
drial DNA is known to be unmethylated, we reasoned that the
high copy number relative to autosomal DNA would not be
appropriate for a PCR-based assay that could be subject to
saturation. To identify autosomal, constitutively unmethy-
lated regions from existing HELP data, we identiﬁed loci
with measured values in at least 340 samples that met strin-
gent criteria for narrow distribution and high HpaII/MspI log211
Figure 3 Determination of normalizing loci. A: Smoothed density es-
timates reﬂecting the number of loci found at each methylation level are
shown. Dashed line shows the bimodal distribution of relative methylation
determined by HELP across all loci in normal CD34þ cells. Solid lines show
the distribution of methylation determined by HELP of the three loci
chosen for signal normalization. All three loci are hypomethylated in most
AML samples and should, therefore, have similar fragment amounts in
MspI- and HpaII-digested samples. B: Comparison of MassArray Epityper to
HELP using unnormalized HELP ratios or HELP ratios normalized to ratios of
the three loci shown in A.
Wertheim et alratio (indicating lack of methylation). Three control loci were
identiﬁed, and their consistent nonmethylated state was
conﬁrmed by plotting the distribution of their methylation
scores across all HELP-analyzed samples3 and comparing it
with the distribution of methylation scores for all loci in a
control, CD34þ cell population (Figure 3A). Normalization
was performed for HELP and MELP by calculating the
average of the log HpaII/MspI ratio for these three control
loci and subtracting from the unnormalized locus of interest.
To demonstrate that this normalization does not signiﬁcantly
affect the results from HELP data that have been previously
subjected to global normalization, we compared the corre-
lation of HELP results with MassArray assessment of
methylation using HELP data subjected to global normali-
zation alone (unnormalized) or to subsequent normalization
using our selected control loci (normalized) (Figure 3B).
Correlation values for these comparisons were essentially
indistinguishable (0.877 unnormalized, 0.873 normalized).
Thus, our normalization to three hypomethylated loci pro-
vides an internal control for the assay and allows for a robust
quantitative analysis of DNAmethylation at the selected loci.
Comparison of MELP and HELP at Individual Loci
Next, we performed the MELP assay on 216 primary AML
samples and determined normalized ratios between MspI-
and HpaII-derived PCR products for those loci whose
methylation status is prognostic for AML. The 216 samples
were chosen from the HOVON data set on which HELP was
previously performed (84 from the training cohort, 84 from
the test cohort, and 48 from the validation cohort3). The
MELP-derived methylation ratios were then compared with
normalized ratios, as determined by the original HELP
assay. As shown in Figure 4A, highly signiﬁcant correla-
tions between HELP and MELP are seen at all loci, indi-
cating that MELP is virtually equivalent to HELP in
determining methylation status for the 18 prognostic loci.
Comparison of MELP and HELP in a Global Methylation
Classiﬁer of AML Patient Prognosis
The strong correlation at each individual locus between the
MspI and HpaII ratios, determined by HELP and MELP,
suggested that methylation status of the 18 prognostic loci, as
determined byMELP, could predict outcome for patientswith
AML. To test this hypothesis, we ﬁrst determined the linear
relationship between normalized HELP and normalized
MELP scores using Deming regression on training samples
that had been measured using both platforms (nZ 84). The
regression curve was then used to convert the normalized
HELP data into a normalized MELP scale, and the full
training set of transformed HELP data (nZ 200) previously
used by Figueroa et al3was used to train an 18-locus classiﬁer.
A predictor was generated using the SuperPC package19
(http://cran.r-project.org/web/packages/superpc/index.html)
in conjunction with training and test sets. Because this212classiﬁer was trained using data that were converted to the
normalizedMELP scale, we then were able to use the test and
validation samples to determine its performance.
By using tertile survival cut points obtained from the
training data set alone, we determined the survival of
methylation-classiﬁed subgroups. As shown in Figure 4B,
transformed HELP data using this predictor are able to
distinguish prognostic classes, and these results are consis-
tent with the previous results of Figueroa et al,3 demon-
strating that methylation (measured by HELP) can predict
prognosis within this disease. To determine whether our
MELP assay can also predict outcome, we performed the
same analysis using samples from the test and validation
samples (n Z 84 and n Z 48, respectively). These results
(Figure 4B) demonstrate that analysis of methylation status
using MELP can predict AML survival (P Z 0.048), thus
showing the suitability of this novel technique for disease
prognosis.Discussion
Although cancer has been traditionally thought of as a
genetic disease driven by the somatic acquisition ofjmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 4 TheMELP assay accurately reﬂects HELP-derived data.A: Comparison of HELP-derived HpaII/MspI ratios (x axis) toMELP-derived ratios (y axis) at the
18 loci used in the methylation classiﬁer for AML (rZ 0.63 to 0.92, P < 1012 for all loci). B: Overall survival curves of AML patients classiﬁed by the 18-locus
methylation score (blue, highest score group; red, middle score group; orange, lowest score group) determined by HELP or MELP. Test and validation cohorts are
shown.
Microsphere DNA Methylation Assaymultiple oncogenic mutations, recent studies have clearly
shown that it is also an epigenetic disease and that dysre-
gulation of chromatin structure plays a central role in
tumorigenesis.2 Despite these associations, routine multi-
locus assessment of epigenetic phenomena is not common,
due in part to the difﬁculty and expense involved in
establishing and performing epigenetic assays. We report
herein the development of a novel assay, MELP, that
measures DNA methylation through the use of ﬂuo-
rescently labeled microspheres and branched DNA hy-
bridization for detection of relevant amplicons. We have
shown that detection of these amplicons by MELP is
highly quantitative and is virtually identical to evaluation
by qPCR. Analysis of DNA methylation at multiple loci by
MELP is tightly correlated with similar evaluation by the
HELP assay.3 Furthermore, methylation analysis at 18 lociThe Journal of Molecular Diagnostics - jmd.amjpathol.orgpreviously shown by HELP to be prognostically relevant in
patients with AML also predicts survival when measured
by MELP.
Unlike most assays that assess DNA methylation at
multiple loci, numerous features of the MELP assay make it
a platform that is well suited to rapidly analyze multilocus
DNA methylation. MELP does not require bisulﬁte treat-
ment of DNA, but rather relies on enzymatic reactions (re-
striction digestion, ligation, and PCR) that are routinely
performed in most molecular laboratories. Evaluation of
methylation is performed by measurement of ﬂuorescent
microspheres and does not require custom-made, solid-
phase oligonucleotide microarrays or high-throughput
sequencing technologies. Indeed, similar analysis of DNA-
coupled ﬂuorescent microspheres is used in a variety of as-
says, including evaluation of recurrent translocations found213
Wertheim et alin AML.17,20 More important, methylation of multiple loci is
evaluated simultaneously using the MELP assay. In our
experiments, two reaction tubes (one each for MspI- and
HpaII-digested DNA) were sufﬁcient for the evaluation of
18 prognostic and three normalization loci. In its current
format, the assay can be expanded to evaluate 80 loci
without a concomitant increase in reactions. This simulta-
neous assessment has clear advantages over independent
parallel reactions (eg, qPCR) in terms of both work ﬂow and
possibility for laboratory errors. In addition, simultaneous
locus evaluation allows for reactions to be internally
controlled for variations in the enzymatic and hybridization
reactions. Finally, the entire assay can be performed in a
relatively short time frame. DNA extraction, digestion, and
linker ligation are performed on the ﬁrst day, PCR and
initial hybridization to the microspheres are performed on
the second day, and ﬁnal branched DNA hybridization and
data collection and analysis are performed on the third day.
Thus, results are typically obtained 2 to 4 days after sample
acquisition.
Although this initial analysis of MELP has been
restricted to patients with AML, the assay platform can
easily be extended to other pathological conditions for
which regulation of DNA methylation has been shown to
have diagnostic, prognostic, or therapeutic implications.
For instance, Shaknovich et al21 have shown that a DNA
methylation signature can classify diffuse large B-cell
lymphomas (DLBCLs) into activated B-cell or germinal
center subtypes, the former of which display a more
aggressive phenotype. In addition, the methylation proﬁle
of DLBCL signiﬁcantly predicts outcome in patients with
activated B-cell DLBCL.22 As such, determination of DNA
methylation status by MELP could aid in subclassiﬁcation
of these tumors.
We and others have examined the role of DNA methyl-
ation as an independent prognostic indicator in AML.3,23
Clearly, survival is inﬂuenced by multiple determinants,
including tumor-speciﬁc events (eg, mutations) and patient-
speciﬁc factors (eg, age, ethnicity, and comorbidities). All of
these factors should be assessed to determine an optimal
algorithm for tumor subclassiﬁcation. The establishment of
MELP allows for DNA methylation analysis to be routinely
incorporated in such studies.Note Added in Proof
Subsequent to the acceptance of this manuscript for publi-
cation, we identiﬁed a correction to the analysis code that
affected a subset of the samples in our original analysis. The
overall results are not affected, and median-cut survival
curves show a signiﬁcant difference (P Z 0.015). This
error, which only affected the survival analysis (Figure 4B),
utilized incorrect values for 17 loci in 17 samples (out of a
total of 216 samples). Corrected analysis code is provided in
the Supplemental Script S6.214Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.jmoldx.2013.10.010.References
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